The DOI matches its Crossref record; 127 of the 143 references it cites were found in a registry or an index; 5 of the 101 sources its claims cite were checked for support.
Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling
Open accessAbstract
Extrapolation of pharmacokinetic (PK) parameters from in vitro or in vivo animal to human is one of the main tasks in the drug development process. Translational approaches provide evidence for go or no-go decision-making during drug discovery and the development process, and the prediction of human PKs prior to the first-in-human clinical trials. In vitro-in vivo extrapolation and allometric scaling are the choice of method for projection to human situations. Although these methods are useful tools for the estimation of PK parameters, it is a challenge to apply these methods since underlying biochemical, mathematical, physiological, and background knowledge of PKs are required. In addition, it is difficult to select an appropriate methodology depending on the data available. Therefore, this review covers the principles of PK parameters pertaining to the clearance, volume of distribution, elimination half-life, absorption rate constant, and prediction method from the original idea to recently developed models in order to introduce optimal models for the prediction of PK parameters.
Overview
CoChat Summary
## TL;DR
This review summarizes in vitro-in vivo extrapolation (IVIVE) and allometric scaling (AS) approaches for predicting human pharmacokinetic parameters from non-clinical data. It argues that both methods are useful, but accuracy depends heavily on choosing the right model and correction factors such as protein binding, blood flow, and species-specific scaling terms.
## Key findings
- For clearance prediction, AS is “a powerful method” for using non-clinical data, but simple AS alone is often insufficient; the review highlights several refinements such as the rule of exponent (ROE), liver blood flow correction, protein binding correction, QSAR, FCIM, and multiexponential allometric scaling.
- The ROE guidance stated in the paper is: exponent 0.55–0.7 → simple AS; 0.71–1.0 → CL × MLP method; >1.0 → CL × BW method.
- In IVIVE, adding correction factors can improve prediction: Lave et al. reported that correcting clearance with in vitro metabolic rates significantly improved prediction of human CL for 10 extensively metabolized drugs; Chiou et al. reported improved prediction for 15 extensively metabolized drugs when protein binding was considered.
- For volume of distribution, the paper reports that Vd is generally well correlated with body weight, with exponents around 1, usually between 0.8 and 1.1; Mahmood and Balian reported average simple-AS exponents of 0.89 (3 species) and 0.90 (2 species).
## Methods
- Narrative review of methods for predicting human PK parameters from non-clinical data, focused on clearance, volume of distribution, elimination half-life, and absorption-related parameters.
- Synthesizes prior studies using in vitro systems (e.g., human liver microsomes, hepatocytes, recombinant CYP systems) and animal PK data across species for IVIVE and AS.
- Compares empirical and physiologically based analyses, including well-stirred and parallel-tube hepatic clearance models, correction-factor approaches, and multiple AS variants.
## Limitations
- The paper states that IVIVE requires substantial PK knowledge, complex mathematical equations, and is expensive and time-consuming.
- The paper states that AS is empirical and can perform poorly for drugs with high protein binding, extensive active renal secretion, transport processes, or species-specific binding/distribution.
- Evident from the text: this is a review article rather than a new experimental study, so its conclusions depend on the quality and scope of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
5 Valid · 6 Not valid · 80 Not checked · 36 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“One of the main reasons associated with the termination of drug development is inappropriate pharmacokinetic (PK) properties in humans [1].”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 1. Introduction
What the sources say
- Supportedcites [1] Prentis, 1988, Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985), Br. J. Clin. Pharm. source
The Abstract (point 4) states that of 198 NCEs discontinued from further development, 'The main reasons for termination were inappropriate pharmacokinetics in man (39.4%), and lack of clinical efficacy (29.3%)'. The Results reinforce this ('the primary cause being inappropriate pharmacokinetics in volunteers (39.4%)' and 'The main reasons for NCEs innovated during the past 20 years being dropped from development were pharmacokinetic difficulties in man or lack of clinical efficacy'). The claim's framing as 'one of the main reasons' matches the source, which is bounded to the 319 NCEs investigated by seven UK-owned companies 1964-1985. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The MA method can successfully predict human clearance.”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 4. Application of AS for the Prediction of Human PK Parameters > 4.2. Prediction of Clearance by AS
What the sources say
- Supportedcites [92] Goteti, 2008, Estimation of human drug clearance using multiexponential techniques, J. Clin. Pharm. source
The Discussion (p. 8) concludes that MA is an improved means of estimating human clearance within acceptable error when preclinical data from more than three species are used. It reports predictions within threefold of measured clearance more than 90% of the time when those species include monkey. This supports the claim that MA can successfully predict human clearance, subject to those conditions. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Their results indicate that monkey is an important species for scaling.”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 4. Application of AS for the Prediction of Human PK Parameters > 4.2. Prediction of Clearance by AS
What the sources say
- Supportedcites [92] Goteti, 2008, Estimation of human drug clearance using multiexponential techniques, J. Clin. Pharm. source
The Discussion (p. 7) explicitly says that analysis of 27 compounds suggested monkey is an important species for interspecies scaling. The Results (p. 6) also report improved human-clearance estimates when monkey was included. (LLM, conf=0.95)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“When the exponent of simple AS was greater than 0.7, MA showed better prediction of human CL than the simple AS method.”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 4. Application of AS for the Prediction of Human PK Parameters > 4.2. Prediction of Clearance by AS
What the sources say
- Supportedcites [92] Goteti, 2008, Estimation of human drug clearance using multiexponential techniques, J. Clin. Pharm. source
The Discussion (p. 8) states that when the simple-allometry slope was greater than 0.7, multiexponential allometry had a clear advantage over simple allometry in predicting human clearance. This analysis concerned 33 of the 50 compounds in data set I. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
In the paper
“Clearance (CL) is considered the most important PK parameter as it is related to drug elimination and bioavailability [27].”
§ Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling > 2. Theoretical Background for the Prediction of Clearance > 2.1. Physiological Clearance Concept
What the sources say
- Not checked — no full text of the sourcecites [27] Zuegge, 2001, Prediction of hepatic metabolic clearance: Comparison and assessment of prediction models, Clin. Pharm. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
72 more claims
Create a free account to see all 127 claims and to verify the 14 references still open.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 31
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×
“Although issues related to PK and bioavailability have improved since the 2000s [4], nearly half of all the therapeutic candidates in drug development are lost due to poor absorption, distribution, metabolism, excretion (ADME), toxicology, and pharmacology (safety) [5].”
BackgroundPhysiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926 · cited 2×
“44 in humans [35] and CRBC refers to the drug concentration in red blood cells.”
BackgroundResultWu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“[87] have suggested a Biopharmaceutics Drug Disposition Classification System (BDDCS), which is modified by the Biopharmaceutics Classification System based on routes of drug elimination and the effect of efflux and absorptive transporters.”
MethodObach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232 · cited 2×
“Obach [62] has reported the prediction method of human intrinsic hepatic clearance (CLint, H, human) using the in vitro half-life (t1/2) to incorporat non-specific binding factors to microsomes (fu,mic) and/or the fp.”
MethodThe Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987 · cited 1×
“Proportionality Vhuman, pred = Vanimal·fu, human fu, animal (95) It is assumed that the volume of distribution at a steady state of free drug is identical between species [120]”
BackgroundUtility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925 · cited 4×
“Although a CLint, in vitro obtained from dexamethasone-treated microsomes provided an accurate estimate of 77% of the observed CLint, in vivo, the limitation similar to that of Houston [60] persisted.”
BackgroundMethodResultInfluentialPang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Clearance concepts in pharmacokinetics
Rowland, M., Benet, L. Z., & Graham, G. G. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059626 · Cited by 649 · cited 2×
“[34]: CLorg = Q·kel·KP·VE Q + kel·KP·VE (10)”
MethodInterspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648
Phase II and phase III failures: 2013–2015
Harrison, R. K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.184 · Cited by 636 · cited 1×
“The main cause of failure in clinical trials is poor efficacy [3].”
BackgroundSimulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami-Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 530 · cited 1×
“The potential variation in the abundance of protein expression in relevant organs can be incorporated into IVIVE [77].”
BackgroundQuantitative Relations in the Physiological Constitutions of Mammals
Adolph, E. F. (1949) · Science · doi:10.1126/science.109.2841.579 · Cited by 500 · cited 1×
“AS assumes that mammals share similar anatomical, biochemical, and physiological features [16,21].”
BackgroundPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).
Prentis, R., Lis, Y., & Walker, Sr. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03318.x · Cited by 471 · cited 1×
“One of the main reasons associated with the termination of drug development is inappropriate pharmacokinetic (PK) properties in humans [1].”
BackgroundBarter, Z., Bayliss, M., Beaune, P., Boobis, A., Carlile, D., Edwards, R., Brian Houston, J., Lake, B., Lipscomb, J., Pelkonen, O., et al. (2007) · Current Drug Metabolism · doi:10.2174/138920007779315053 · Cited by 459
A compartmental absorption and transit model for estimating oral drug absorption
Yu, L. X., & Amidon, G. L. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00147-7 · Cited by 455
Winiwarter, S., Bonham, N. M., Ax, F., Hallberg, A., Lennernäs, H., & Karlén, A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810102 · Cited by 453 · cited 1×
“239HBD (103) The choice of model for prediction depends on the availability of descriptor data Effective permeability in 10−4 cm/s [124] logPeff = −2.”
BackgroundSun, D., Lennernas, H., Welage, L. S., Barnett, J. L., Landowski, C. P., Foster, D., Fleisher, D., Lee, K.-D., & Amidon, G. L. (2002) · Pharmaceutical Research · doi:10.1023/a:1020483911355 · Cited by 447
Austin, R. P., Barton, P., Cockroft, S. L., Wenlock, M. C., & Riley, R. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1497 · Cited by 413
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397 · cited 1×
“The allometric equation is generally expressed as a power function based on the following equation [20]: Y = aWb (73)”
MethodBoxenbaum, H. (1980) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01065191 · Cited by 347
EVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS
Shitara, Y., Sato, H., & Sugiyama, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121444 · Cited by 336 · cited 1×
“In the disposition process, transporters and enzymes play a key role by interacting with each other [86].”
BackgroundPrediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.
Rane, A., Wilkinson, G. R., & Shand, D. G. (1977) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30786-x · Cited by 328 · cited 1×
“Since a maximum limit for microsomal CL may exist [59], drugs with high CL tend to have under-predicted CLint, in vivo if data are derived from microsomal protein [51].”
Background(2001) · PubMed · Cited by 316
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300 · cited 1×
“A few studies have reported AS using only one or two species [90,94,95].”
BackgroundInterspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm
Boxenbaum, H. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033558 · Cited by 267 · cited 1×
“Two-term method CL = θ(W)·(BW) (77) θ is a constant, which is determined by multiple regression analysis [91]”
MethodA dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations
Roberts, M. S., & Rowland, M. (1986) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01106706 · Cited by 261 · cited 1×
“There have been efforts to explain hepatic clearance as more physiologically relevant by using a dispersion model [48,49] or a distributed model [50,51].”
BackgroundIto, K., & Houston, J. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9015-1 · Cited by 260 · cited 1×
“A few studies have reported AS using only one or two species [90,94,95].”
BackgroundInterspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Effect of Altered Plasma Protein Binding on Apparent Volume of Distribution
Øie, S., & Tozer, T. N. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680948 · Cited by 256
Effects of Liver Disease on Pharmacokinetics: An Update
Rodighiero, V. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937050-00004 · Cited by 235
Compartmental transit and dispersion model analysis of small intestinal transit flow in humans
Yu, L. X., Crison, J. R., & Amidon, G. L. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(96)04592-9 · Cited by 231 · cited 1×
“025 × 10−3 min−1 as an inverse value of the average transit time [130] in human small intestine (approximately 199 min).”
BackgroundPrediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
Howgate, E. M., Rowland Yeo, K., Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600683197 · Cited by 223 · cited 1×
“[65] revealed that most of the fu,mic values are high enough to be ignored in the prediction of clearance.”
BackgroundRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors
Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2004) · Xenobiotica · doi:10.1080/00498250310001646353 · Cited by 219 · cited 1×
“RAF = Vmax(HML) Vmax(rhCYP) (52) Relative activity factor (RAF) introduced for scaling rhCYP data to HLM Modified RAF taking into account of Km [69,70] RAF = CLint(HML) CLint(rhCYP) (53)”
MethodPang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059689 · Cited by 217
Achour, B., Barber, J., & Rostami-Hodjegan, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058834 · Cited by 212 · cited 5×
“It is used to direct scale data from a rhCYP system to an HLM environment for evaluation of differences in intrinsic activity (per unit CYP) and IIV by incorporating CYP abundance as shown in Equations (52) to (56).”
BackgroundInfluentialRing, B. J., Chien, J. Y., Adkison, K. K., Jones, H. M., Rowland, M., Jones, R. D., Yates, J. W. T., Ku, M. S., Gibson, C. R., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22552 · Cited by 206 · cited 1×
“Although it is theoretically feasible to use AS with unbound clearance (CLu = CL/fu) based on protein binding, in practice, fu does not significantly improve its predictability [22], [113].”
Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202 · cited 1×
“75 cm) [129], and L is the length of perfusion segment (10 cm).”
BackgroundVenkatakrishnan, K., von Moltke, L. L., Court, M. H., Harmatz, J. S., Crespi, C. L., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13680-x · Cited by 200 · cited 1×
“[81] have also investigated the role of CYP1A2, CYP2B6, CYP2C19, CYP3A, and CYP2D6 in a lymphoblastic cell line and suggested the incorporation of bridging factors between rhCYP and liver microsomes, such as RAF and abundance of CYP isoform in microsomes.”
BackgroundLave, T. H., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960440h · Cited by 184 · cited 2×
“[93] have investigated in vitro data with AS to predict hepatic clearance for 10 drugs that are extensively metabolized.”
BackgroundAndrade, E. L., Bento, A. F., Cavalli, J., Oliveira, S. K., Schwanke, R. C., Siqueira, J. M., Freitas, C. S., Marcon, R., & Calixto, J. B. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165646 · Cited by 184
Basic Principles of Pharmacokinetics
Benet, L. Z., & Zia-Amirhosseini, P. (1995) · Toxicologic Pathology · doi:10.1177/019262339502300203 · Cited by 179 · cited 1×
“It is expressed by the following equation [33]:”
BackgroundPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178 · cited 8×
“5 ka = 2Peff R (112) The absorption rate constant is proportional to the Peff [126]”
BackgroundInfluential(1998) · PubMed · Cited by 176
MAHMOOD, I. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.015 · Cited by 170 · cited 16×
“In their studies, they compared the CL value of antiepileptic drugs using four different allometric equations: a simple AS in Equation (74), the product of CL and MPL in Equation (75), the Boxenbaum’s two-term power function in Equation (77), and the product of CL and BW in Equation (76), a novel equation developed by…”
MethodInfluentialInitial distribution and rate of uptake of sulfobromophthalein in the liver
Goresky, C. A. (1964) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1964.207.1.13 · Cited by 164
Lav??, T., Coassolo, P., & Reigner, B. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00003 · Cited by 162 · cited 1×
“A reliable extrapolation method to predict hepatic metabolic clearance utilizes in vitro kinetic data and mathematical equations [58].”
MethodInterspecies scaling and comparisons in drug development and toxicokinetics
Ings, R. M. J. (1990) · Xenobiotica · doi:10.3109/00498259009046839 · Cited by 151 · cited 1×
“Animal PK data are routinely obtained in non-clinical drug development processes [26].”
BackgroundInterspecies Prediction of Human Drug Clearance Based on Scaling Data from One or Two Animal Species
Tang, H., Hussain, A., Leal, M., Mayersohn, M., & Fluhler, E. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016188 · Cited by 150 · cited 3×
“152·CLrat· ( Whuman Wrat ) (81) Predict the CL of bound drug [90] CLpred = 0.”
BackgroundMethodHuang, Q., & Riviere, J. E. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.934671 · Cited by 149 · cited 3×
“Although it is theoretically feasible to use AS with unbound clearance (CLu = CL/fu) based on protein binding, in practice, fu does not significantly improve its predictability [22], [113].”
BackgroundMethodA NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004143 · Cited by 141 · cited 1×
“77 (87) Rfu is the fu ratio between rats and humans and a is the coefficient form AS The unit of CL is mL/min [97]”
BackgroundRelation of Lifespan to Brain Weight and Body Weight in Mammals
Sacher, G. A. (2008) · Novartis Foundation symposium · doi:10.1002/9780470715253.ch9 · Cited by 138
Barter, Z. E., Chowdry, J., HARLOW, J., SNAWDER, J. E., Lipscomb, J. C., & Rostami‐Hodjegan, A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021311 · Cited by 134 · cited 11×
“The authors also provided the following equation to calculate age-related values of MPPGL from birth to adult: MPPGL (mg/g) = 10(1.407+0.0158×age−0.00038×age 2+0.0000024×age3 (72) The results provide key information to project PK parameters to humans, especially prior to clinical trials.”
BackgroundInfluential(1997) · PubMed · Cited by 121
Sawada, Y., Hanano, M., Sugiyama, Y., & Iga, T. (1984) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061720 · Cited by 117 · cited 1×
“[118], the authors investigated the prediction of disposition of beta-lactam antibiotics and reported large differences in free volume of distribution between species.”
BackgroundHepatic elimination of flowing substrates: The distributed model
Bass, L., Robinson, P., & Bracken, A. J. (1978) · Journal of Theoretical Biology · doi:10.1016/0022-5193(78)90023-1 · Cited by 116 · cited 2×
“Since a maximum limit for microsomal CL may exist [59], drugs with high CL tend to have under-predicted CLint, in vivo if data are derived from microsomal protein [51].”
BackgroundThe Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols
Mahmood, I., & Balian, J. D. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936010-00001 · Cited by 112 · cited 17×
“In their studies, they compared the CL value of antiepileptic drugs using four different allometric equations: a simple AS in Equation (74), the product of CL and MPL in Equation (75), the Boxenbaum’s two-term power function in Equation (77), and the product of CL and BW in Equation (76), a novel equation developed by…”
BackgroundInfluentialPoulin, P., Kenny, J. R., Hop, C. E. C. A., & Haddad, S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22792 · Cited by 109 · cited 2×
“3 [72] fu,liver = PLR·fu,p,app 1+(PLR−1)·fu,p,app (62)”
BackgroundLavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Pharmaceutical Research · doi:10.1023/a:1012036324237 · Cited by 106 · cited 3×
“7 [61] ERH,pred = SF·CLint,in vitro QH+(SF·CLint,in vitro) (41)”
BackgroundMethodInfluentialMahmood, I., & Balian, J. D. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950400y · Cited by 105 · cited 17×
“Because of the hybrid nature of the t1/2, this parameter has been poorly estimated by AS [89,114].”
BackgroundMethodResultInfluentialChen, Y., Liu, L., Nguyen, K., & Fretland, A. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035147 · Cited by 104 · cited 1×
“[80] have experimentally determined the ISEF of six CYP isoforms and investigated their utility in early phases of drug discovery and development.”
BackgroundRed cell carriage of label: its limiting effect on the exchange of materials in the liver.
Goresky, C. A., Bach, G. G., & Nadeau, B. E. (1975) · Circulation Research · doi:10.1161/01.res.36.2.328 · Cited by 103
(2004) · Cited by 101
Roberts, M. S., & Rowland, M. (1986) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01106707 · Cited by 98 · cited 1×
“There have been efforts to explain hepatic clearance as more physiologically relevant by using a dispersion model [48,49] or a distributed model [50,51].”
BackgroundNagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96 · cited 4×
“Hepatic liver method CLpred = CLanimal· ( QH,human QH,animal ) (86) [96]”
BackgroundMethodInfluentialNakajima, M., Nakamura, S., Tokudome, S., Shimada, N., Yamazaki, H., & Yokoi, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14947-1 · Cited by 94 · cited 8×
“[69] have suggested a modified version of the relative activity factor (RAF) using CLint, in vitro to correct a flaw in the original RAF, which was calculated with Vmax alone while the Km value was ignored.”
MethodInfluentialSnawder, J. E., & Lipscomb, J. C. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1424 · Cited by 93 · cited 5×
“It is used to direct scale data from a rhCYP system to an HLM environment for evaluation of differences in intrinsic activity (per unit CYP) and IIV by incorporating CYP abundance as shown in Equations (52) to (56).”
BackgroundInfluentialPrediction of Hepatic Metabolic Clearance: Comparison and Assessment of Prediction Models
Zuegge, J., Schneider, G., Coassolo, P., & Lav??, T. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00006 · Cited by 92 · cited 1×
“Clearance (CL) is considered the most important PK parameter as it is related to drug elimination and bioavailability [27].”
BackgroundScaling basic toxicokinetic parameters from rat to man.
Bachmann, K., Pardoe, D., & White, D. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104400 · Cited by 90 · cited 1×
“35Vrat (96) Statistical modeling is applied in this model [121]”
MethodOrgan Clearance Concepts: New Perspectives on Old Principles
Sirianni, G. L., & Pang, K. S. (1997) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1023/a:1025792925854 · Cited by 89
Prediction of metabolic drug clearance in humans:In vitro–in vivoextrapolationvsallometric scaling
Shiran, M. R., Proctor, N. J., Howgate, E. M., Rowland-Yeo, K., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600761662 · Cited by 89 · cited 1×
“Some researchers have expressed concerns about AS since correction factors such as MLP and BW have no clear biological rationale [107].”
BackgroundSawada, Y., Hanano, M., Sugiyama, Y., & Iga, T. (1985) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059331 · Cited by 87 · cited 1×
“[117] have reported that considering the unbound fraction in the prediction of Vd may increase the accuracy of prediction results than the volume against unbound fraction in the plasma.”
BackgroundScaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species
Boxenbaum, H. G., & Fertig, J. B. (1984) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03189622 · Cited by 85 · cited 2×
“Two-Term Method Boxenbaum and Fertig [17] have developed the two-term method.”
MethodPhysiologic pharmacokinetic models and interanimal species scaling
Rowland, M. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90016-6 · Cited by 84 · cited 1×
“, sinusoids and hepatocytes) exponentially decreases in the direction of the hepatic vein [39].”
BackgroundPang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059690 · Cited by 77
Camenisch, G., & Umehara, K. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1784 · Cited by 76 · cited 16×
“However, this modified equation also improves the prediction of CLH for acidic compounds.”
BackgroundMethodInfluentialNishimuta, H., Houston, J. B., & Galetin, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057372 · Cited by 75 · cited 1×
“, biliary [10], renal [11–13], glucuronidation [11], and hydrolysis [14] clearance), we focus on the prediction of hepatic clearance which is the primary elimination pathway.”
BackgroundMahmood, I., & Balian, J. D. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00339-6 · Cited by 72 · cited 8×
“In their studies, they compared the CL value of antiepileptic drugs using four different allometric equations: a simple AS in Equation (74), the product of CL and MPL in Equation (75), the Boxenbaum’s two-term power function in Equation (77), and the product of CL and BW in Equation (76), a novel equation developed by…”
BackgroundMethodInfluentialWajima, T., Fukumura, K., Yano, Y., & Oguma, T. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10242 · Cited by 72 · cited 2×
“707 (88) The unit of observed and predicted CL value is mL/min/kg [98]”
BackgroundSpecies Differences in Distribution and Prediction of Human Vss from Preclinical Data
Berry, L. M., Li, C., & Zhao, Z. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040766 · Cited by 69 · cited 1×
“For a drug with low binding affinity to plasma and tissue protein or drugs that are only distributed in the extracellular space, they can be scaled since total body water and extracellular water shows inverse correlation with animal size in AS [116].”
BackgroundLi, J., Wu, J., Bao, X., Honea, N., Xie, Y., Kim, S., Sparreboom, A., & Sanai, N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0983 · Cited by 68 · cited 1×
“Although to project in vitro to in vivo data is difficult due to the complexity of the interdependent biological processes and their dynamic nature [7], it is more physiologically relevant than AS, considering that IVIVE incorporates physiological factors and includes the possibility to expand with the mechanistic mod…”
BackgroundUsansky, H. H., & Sinko, P. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.076182 · Cited by 67 · cited 1×
“47 (113) Fa is expressed as percent unit The equation is the result of the correlation between Fa,pred and Fa,exp [127] ka,eq = PmS Vc (114) ka,eq is expressed as the unit of min−1 ka,eq is a key determinant for Fa and can be used as PK modeling Fa = ka,eq ki+ka,eq (115)”
(2004) · PubMed · Cited by 66
Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat
Umehara, K.-I., & Camenisch, G. (2012) · Pharmaceutical Research · doi:10.1007/s11095-011-0607-2 · Cited by 65 · cited 2×
“CLint,liver,invitro = PSuptake,total· CLmet+PSbile CLmet+PSefflux,total+PSbile (63) Physiologically-based IVIVE model Total apparent uptake clearance (PSuptake,total) consists of saturable and/or non-saturable processes CLmet and PSbile refer to metabolic and biliary clearance, respectively Apparent sinusoidal total e…”
BackgroundMethodPoulin, P., Hop, C. E. C. A., Ho, Q., Halladay, J. S., Haddad, S., & Kenny, J. R. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23288 · Cited by 64 · cited 1×
“[72,83,84] have developed a mechanistic IVIVE model based on two additional factors including pH differences between extracellular and intracellular water in liver, and protein-facilitated uptake induced by potential ionic interactions between protein-albumin bound drug complex and cell surface.”
BackgroundBerezhkovskiy, L. M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22324 · Cited by 63 · cited 2×
“Berezhkovskiy [71] has developed a modified equation to predict CLH based on differences in intra- and extra-cellular pH of the unbound drug fraction using FI as presented in Equations (57) to (60).”
BackgroundMethodInterspecies scaling of biliary excreted drugs
Mahmood, I., & Sahajwalla, C. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10174 · Cited by 62 · cited 1×
“The predictability of human CL is significantly improved using the bile flow correction factor [110].”
MethodAdvanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts
Pang, K. S., Weiss, M., & Macheras, P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902030 · Cited by 61
Hallifax, D., & Houston, J. B. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23202 · Cited by 60 · cited 5×
“As shown in these results of Houston [46] and Lavé et al. [47], appropriate scaling factors are important in the IVIVE model to improve the predictability.”
ResultInfluentialWeiss, M., & Roberts, M. S. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353488 · Cited by 59
Poulin, P., & Haddad, S. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23502 · Cited by 54 · cited 1×
“[72,83,84] have developed a mechanistic IVIVE model based on two additional factors including pH differences between extracellular and intracellular water in liver, and protein-facilitated uptake induced by potential ionic interactions between protein-albumin bound drug complex and cell surface.”
BackgroundMahmood, I. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb06190.x · Cited by 53 · cited 8×
“Because of the hybrid nature of the t1/2, this parameter has been poorly estimated by AS [89,114].”
BackgroundInfluentialScotcher, D., Jones, C. R., Posada, M. M., Rostami‐Hodjegan, A., & Galetin, A. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9942-x · Cited by 50
Knights, K., Spencer, S. M., Fallon, J. K., Chau, N., Smith, P. C., & Miners, J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12889 · Cited by 49 · cited 1×
“, biliary [10], renal [11–13], glucuronidation [11], and hydrolysis [14] clearance), we focus on the prediction of hepatic clearance which is the primary elimination pathway.”
BackgroundScotcher, D., Billington, S. F., Brown, J., Jones, C. R., Brown, C., Rostami‐Hodjegan, A., & Galetin, A. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.075242 · Cited by 48
Model-based drug development: application of modeling and simulation in drug development
Kim, T., Shin, S., & Shin, B. S. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0371-3 · Cited by 45 · cited 1×
“Therefore, predicting drug behavior in the liver facilitates the analysis of hepatic drug elimination in virtual scenarios [38].”
BackgroundClearance Concepts: Fundamentals and Application to Pharmacokinetic Behavior of Drugs
Mehvar, R. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps29896 · Cited by 39
Interspecies Scaling: Role of Protein Binding in the Prediction of Clearance from Animals to Humans
Mahmood, I. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001214 · Cited by 38 · cited 1×
“Mahmood [104] has investigated the role of protein binding in the prediction of CL using 20 randomly selected drugs.”
MethodThe series-compartment model for hepatic elimination.
Gray, M. R., & Tam, Y. K. (1987) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06604-8 · Cited by 37 · cited 1×
“Other models presented by scholars include the series-compartment model [53] and transit-time model [54–57].”
MethodWajima, T., Fukumura, K., Yano, Y., & Oguma, T. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021477 · Cited by 36 · cited 1×
“71 (97) Vdss, human (mL/kg) is predicted by QSAR modeling with quadratic term descriptors [122]”
MethodGeng, W. P., Schwab, A., Goresky, C. A., et al. (1995) · Hepatology · doi:10.1002/hep.1840220427 · Cited by 36
Wajima, T., Fukumura, K., Yano, Y., & Oguma, T. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10510 · Cited by 34 · cited 2×
“[98,99] have tried to predict human CL based on physicochemical properties of drugs.”
BackgroundMahmood, I. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20650 · Cited by 34 · cited 16×
“However, when Mahmood [106] performed comparative analysis using ROE and FCIM for drugs with various PK properties (i.”
MethodInfluentialMukkavilli, R., Pinjari, J., Patel, B., Sengottuvelan, S., Mondal, S., Gadekar, A. R., Verma, M., Patel, J., Pothuri, L., Chandrashekar, G., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.09.006 · Cited by 34 · cited 1×
“Integration of the in vitro data and in vivo animal data is recommended for accurate prediction of specific ADME processes in humans [7] and recently, the combined methods were applied to a drug development process [123,131].”
MethodInterspecies Scaling: Predicting Oral Clearance in Humans
Mahmood, I. (2002) · American Journal of Therapeutics · doi:10.1097/00045391-200201000-00008 · Cited by 33 · cited 1×
“Mahmood [103] also tested the ROE to predict oral clearance by the same approach.”
MethodPharmacogenetics‐Based New Therapeutic Concepts
Roots, I., Gerloff, T., Meisel, C., Kirchheiner, J., Goldammer, M., Kaiser, R., Laschinski, G., Brockmöller, J., Cascorbi, I., Kleeberg, U., et al. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033458 · Cited by 33 · cited 1×
“The prediction of human CLH by IVIVE is generally limited by IIV, most likely due to drug metabolizing enzymes [74].”
BackgroundThe extended clearance model and its use for the interpretation of hepatobiliary elimination data
Camenisch, G., Riede, J., Kunze, A., Huwyler, J., Poller, B., & Umehara, K. (2015) · ADMET & DMPK · doi:10.5599/admet.3.1.144 · Cited by 32
Mahmood (2002) · Drug Metabolism and Drug Interactions · doi:10.1515/dmdi.2002.19.1.49 · Cited by 29 · cited 15×
“In their studies, they compared the CL value of antiepileptic drugs using four different allometric equations: a simple AS in Equation (74), the product of CL and MPL in Equation (75), the Boxenbaum’s two-term power function in Equation (77), and the product of CL and BW in Equation (76), a novel equation developed by…”
ResultInfluentialChiou, W. L., & Hsu, F.-H. (1988) · Pharmaceutical Research · doi:10.1023/a:1015935206569 · Cited by 28 · cited 1×
“[112] have reported the effect of protein binding on prediction of human clearance in AS for 15 extensively metabolized drugs.”
BackgroundEstimation of Human Drug Clearance Using Multiexponential Techniques
Goteti, K., Brassil, P. J., Good, S. S., & Garner, C. E. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008320369 · Cited by 28 · cited 1×
“[92] have developed a new method for animal scale up using MA.”
MethodHepatocyte [3H]-palmitate uptake: effect of albumin surface charge modification
Burczynski, F. J., Wang, G. Q., Elmadhoun, B., She, Y. M., Roberts, M. S., & Standing, K. G. (2001) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y01-072 · Cited by 28
Can Allometric Interspecies Scaling be Used to Predict Human Kinetics?
Campbell, D. B. (1994) · Drug Information Journal · doi:10.1177/009286159402800130 · Cited by 26
Hepatic Clearance Measurements and Pharmacokinetics
Keiding, S., & Buch Andreasen, P. (2008) · Pharmacology · doi:10.1159/000137296 · Cited by 23 · cited 1×
“Typically ER decreases with increasing QH [32].”
Albumin Binding and Hepatic Uptake: The Importance of Model Selection
Forker, E. L., & Luxon, B. A. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600721038 · Cited by 22 · cited 2×
“[47], appropriate scaling factors are important in the IVIVE model to improve the predictability.”
BackgroundSawada, Y., Sugiyama, Y., Miyamoto, Y., Iga, T., & Hanano, M. (1985) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.33.319 · Cited by 22 · cited 1×
“There have been efforts to explain hepatic clearance as more physiologically relevant by using a dispersion model [48,49] or a distributed model [50,51].”
Background(1973) · PubMed · Cited by 21
Riede, J., Poller, B., Umehara, K.-I., Huwyler, J., & Camenisch, G. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.02.022 · Cited by 21 · cited 2×
“Although to project in vitro to in vivo data is difficult due to the complexity of the interdependent biological processes and their dynamic nature [7], it is more physiologically relevant than AS, considering that IVIVE incorporates physiological factors and includes the possibility to expand with the mechanistic mod…”
BackgroundMethodZou, P., Liu, X., Wong, S., Feng, M. R., & Liederer, B. M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23620 · Cited by 19 · cited 1×
“, biliary [10], renal [11–13], glucuronidation [11], and hydrolysis [14] clearance), we focus on the prediction of hepatic clearance which is the primary elimination pathway.”
BackgroundForker, L. E., & Luxon, B. A. (1985) · Hepatology · doi:10.1002/hep.1840050630 · Cited by 18 · cited 6×
“Therefore, unless there is obvious evidence, most investigators use the well-stirred model based on the principle that models should be as simple as possible, but not simpler [40,46].”
MethodResultInfluentialLiu, D., Ma, X., Liu, Y., Zhou, H., Shi, C., Wu, F. S.-Y., Jiang, J., & Hu, P. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.020 · Cited by 16 · cited 2×
“Integration of the in vitro data and in vivo animal data is recommended for accurate prediction of specific ADME processes in humans [7] and recently, the combined methods were applied to a drug development process [123,131].”
MethodThe Correction Factors Do Help in Improving the Prediction of Human Clearance from Animal Data
Mahmood, I. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20299 · Cited by 13 · cited 16×
“In their studies, they compared the CL value of antiepileptic drugs using four different allometric equations: a simple AS in Equation (74), the product of CL and MPL in Equation (75), the Boxenbaum’s two-term power function in Equation (77), and the product of CL and BW in Equation (76), a novel equation developed by…”
MethodInfluentialPharmacokinetics in liver disease
Breimer, D. D. (1987) · Pharmacy World & Science · doi:10.1007/bf01960740 · Cited by 11 · cited 1×
“Alteration of liver blood flow, synthesis of albumin, and/or enzyme activity could occur by liver impairment, concomitant drug use, environmental factors, and so on [36,37].”
Background(2006) · PubMed · Cited by 8
Joshi, G. P. (2004) · PubMed · Cited by 4
Temerin, L. A. (1985) · American Journal of Physical Anthropology · doi:10.1002/ajpa.1330660313 · Cited by 3
Research works printed but not linked: 4
- Shargel, L., Andrew, B.C., and Wu-Pong, S. (2016). Applied Biopharmaceutics & Pharmacokinetics, Appleton & Lange Reviews/McGraw-Hill, Medical Pub. Division. [7th ed.].
- Weiner, J.G.D. (2016). Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press. [5th ed.].
- Carlile, 1997, Scaling factors to relate drug metabolic clearance in hepatic microsome, isolated hepatocytes, and the intact liver, Drug Metab. Dispos., 25, 903
- Kenyon, E.M. (2012). Computational Toxicology: Methods in Molecular Biology, Humana Press.
Cited by
Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00352 · Cited by 132
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials
Ozbek, O., Genc, D. E., & Ülgen, K. Ö. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00250 · Cited by 102
“68 The pharmacokinetics of 46, 69, 113, and 162 nm of mesoporous silica NPs was investigated following their intravenous administration to rats.”
New approach methodologies (NAMs) for human-relevant biokinetics predictions
Punt, A., Bouwmeester, H., Blaauboer, B. J., Coecke, S., Hakkert, B., Hendriks, D. F. G., Jennings, P., Kramer, N. I., Neuhoff, S., Masereeuw, R., et al. (2020) · ALTEX · doi:10.14573/altex.2003242 · Cited by 77
“…on the principle of the test, the experimental set-up, the inclusion of reference compounds, the calculation of the in vitro results (correction factors applied or modelling of the in vitro data), and the reporting of the results (Choi et al., 2019; Fisher et al., 2019; Jamei et al., 2009b).”
ResultMurad, N., Pasikanti, K. K., Madej, B. D., Minnich, A., McComas, J., Crouch, S., Polli, J. W., & Weber, A. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000202 · Cited by 60
“Although allometry has some limitations in predicting distribution of highly protein-bound drugs, it has been a valuable technique to predict human PK parameters to determine first-time-in-human dose (Choi et al., 2019).”
MethodYadav, J., Hassani, M. E., Sodhi, J. K., Lauschke, V. M., Hartman, J. H., & Russell, L. E. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1922435 · Cited by 62
“Despite a wealth of in vitro data, predicting in vivo metabolism clearance and transporter-mediated clearance remains complex, often resulting in under-predictions of in vivo clearance (Wood et al. 2017; Chothe et al. 2018; Choi et al. 2019; Liang et al. 2020).”
Background
Metadata
- Authors
- Choi, G.-W., Lee, Y.-B., & Cho, H.-Y.
- Affiliations
- CHA University (KR)
- Chonnam National University (KR)
- Corresponding author
- Cho, Hea-Young
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2019-04-05
- Volume
- 11
- Issue
- 4
- Pages
- 168
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC6523982
- OpenAlex
- W2930584951
- Cited by
- 79
- References
- 143
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 14 · 2023: 7 · 2022: 14 · 2021: 11 · 2020: 12 · 2019: 1
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- in vitro-in vivo extrapolation, allometric scaling, human pharmacokinetic prediction, drug development, clearance, volume of distribution, elimination half-life, absorption rate constant, translational toxicology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.